Alphavirus vectors for cancer therapy

Virus Research

Volumn 153, Issue 2, 2010, Pages 179-196

  Quetglas, Jose I ^a   Ruiz Guillen, Marta ^a   Aranda, Alejandro ^a   Casales, Erkuden ^a   Bezunartea, Jaione ^a   Smerdou, Cristian ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alphavirus; Cancer; Gene therapy; Vaccine

Indexed keywords

ALPHAVIRUS VECTOR; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; MELANOMA ANTIGEN; MICRORNA; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALPHA VIRUS; ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUSION; DENDRITIC CELL; EXPRESSION VECTOR; LIFE CYCLE; MASTOCYTOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MODIFICATION; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SINDBIS VIRUS; SUICIDE GENE; VIRAL GENE THERAPY; WART VIRUS;

ALPHAVIRUS; ANIMALS; APOPTOSIS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERFERON TYPE I; MALE; MAMMARY NEOPLASMS, ANIMAL; MASTOCYTOMA; MELANOMA; MODELS, ANIMAL; NEOPLASMS; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS;

ALPHAVIRUS; ANIMALIA; EUKARYOTA; SEMLIKI FOREST VIRUS; SINDBIS VIRUS;

EID: 77957282818     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.07.027     Document Type: Review

References (176)

1. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
2. Asselin-Paturel C., Lassau N., Guinebretiere J.M., Zhang J., Gay F., Bex F., Hallez S., Leclere J., Peronneau P., Mami-Chouaib F., Chouaib S. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 1999, 6:606-615.
3. Barry G., Fragkoudis R., Ferguson M.C., Lulla A., Merits A., Kohl A., Fazakerley J.K. Semliki forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of Mammalian cells. J. Virol. 2010, 84:7369-7377.
4. Berglund P., Fleeton M.N., Smerdou C., Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999, 17:497-507.
5. Berglund P., Sjöberg M., Garoff H., Atkins G.J., Sheahan B.J., Liljeström P. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N.Y.) 1993, 11:916-920.
6. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., Liljeström P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 1998, 16:562-565.
7. Brault A.C., Foy B.D., Myles K.M., Kelly C.L., Higgs S., Weaver S.C., Olson K.E., Miller B.R., Powers A.M. Infection patterns of o'nyong nyong virus in the malaria-transmitting mosquito, Anopheles gambiae. Insect Mol. Biol. 2004, 13:625-635.
8. Bredenbeek P.J., Frolov I., Rice C.M., Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J. Virol. 1993, 67:6439-6446.
9. Casales E., Aranda A., Quetglas J.I., Ruiz-Guillen M., Rodriguez-Madoz J.R., Prieto J., Smerdou C. A novel system for the production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector. N. Biotechnol. 2010, 27:138-148.
10. Casales E., Rodriguez-Madoz J.R., Ruiz-Guillen M., Razquin N., Cuevas Y., Prieto J., Smerdou C. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability. Virology 2008, 376:242-251.
11. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., Smith L.R., Kast W.M. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22:520-527.
12. Colmenero P., Chen M., Castanos-Velez E., Liljeström P., Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 2002, 98:554-560.
13. Colmenero P., Liljeström P., Jondal M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther. 1999, 6:1728-1733.
14. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., Hunter C.A., Fox J.C., Trinchieri G., Lee W.M. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 1998, 101:1441-1452.
15. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Rice C.M., Ling M., Wu T.C. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J. Immunol. 2001, 166:6218-6226.
16. Cheng W.F., Hung C.F., Hsu K.F., Chai C.Y., He L., Ling M., Slater L.A., Roden R.B., Wu T.C. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum. Gene Ther. 2001, 12:235-252.
17. Cheng W.F., Hung C.F., Hsu K.F., Chai C.Y., He L., Polo J.M., Slater L.A., Ling M., Wu T.C. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 2002, 13:553-568.
18. Cheng W.F., Hung C.F., Lee C.N., Su Y.N., Chang M.C., He L., Wu T.C., Chen C.A., Hsieh C.Y. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur. J. Immunol. 2004, 34:1892-1900.
19. Cheng W.F., Hung C.H., Chai C.Y., Hsu K.F., He L., Ling M., Wu T.C. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001, 75:2368-2376.
20. Cheng W.F., Lee C.N., Su Y.N., Chai C.Y., Chang M.C., Polo J.M., Hung C.F., Wu T.C., Hsieh C.Y., Chen C.A. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther. 2006, 13:873-885.
21. Chikkanna-Gowda C.P., McNally S., Sheahan B.J., Fleeton M.N., Atkins G.J. Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18. Oncol. Rep. 2006, 16:713-719.
22. Chikkanna-Gowda C.P., Sheahan B.J., Fleeton M.N., Atkins G.J. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 2005, 12:1253-1263.
23. Daemen T., Pries F., Bungener L., Kraak M., Regts J., Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 2000, 7:1859-1866.
24. Daemen T., Regts J., Holtrop M., Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 2002, 9:85-94.
25. Daemen T., Riezebos-Brilman A., Bungener L., Regts J., Dontje B., Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003, 21:1082-1088.
26. Daemen T., Riezebos-Brilman A., Regts J., Dontje B., van der Zee A., Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir. Ther. 2004, 9:733-742.
27. Das T., Jaffar-Bandjee M.C., Hoarau J.J., Krejbich Trotot P., Denizot M., Lee-Pat-Yuen G., Sahoo R., Guiraud P., Ramful D., Robin S., Alessandri J.L., Gauzere B.A., Gasque P. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog. Neurobiol. 2010, 91:121-129.
28. Davis N.L., Willis L.V., Smith J.F., Johnston R.E. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 1989, 171:189-204.
29. DiCiommo D.P., Bremner R. Rapid, high level protein production using DNA-based Semliki Forest virus vectors. J. Biol. Chem. 1998, 273:18060-18066.
30. Diebold S.S., Montoya M., Unger H., Alexopoulou L., Roy P., Haswell L.E., Al-Shamkhani A., Flavell R., Borrow P., Reis e Sousa C. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003, 424:324-328.
31. Diebold S.S., Schulz O., Alexopoulou L., Leitner W.W., Flavell R.A., Reis e Sousa C. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther. 2009, 16:359-366.
32. Donnelly M.L., Luke G., Mehrotra A., Li X., Hughes L.E., Gani D., Ryan M.D. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. 2001, 82:1013-1025.
33. Doronina V.A., Wu C., de Felipe P., Sachs M.S., Ryan M.D., Brown J.D. Site-specific release of nascent chains from ribosomes at a sense codon. Mol. Cell. Biol. 2008, 28:4227-4239.
34. Dubensky T.W., Driver D.A., Polo J.M., Belli B.A., Latham E.M., Ibanez C.E., Chada S., Brumm D., Banks T.A., Mento S.J., Jolly D.J., Chang S.M. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 1996, 70:508-519.
35. Dubuisson J., Rice C.M. Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells. J. Virol. 1993, 67:3363-3374.
36. Durso R.J., Andjelic S., Gardner J.P., Margitich D.J., Donovan G.P., Arrigale R.R., Wang X., Maughan M.F., Talarico T.L., Olmsted R.A., Heston W.D., Maddon P.J., Olson W.C. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res. 2007, 13:3999-4008.
37. Eiben G.L., Velders M.P., Schreiber H., Cassetti M.C., Pullen J.K., Smith L.R., Kast W.M. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002, 62:5792-5799.
38. Eralp Y., Wang X., Wang J.P., Maughan M.F., Polo J.M., Lachman L.B. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004, 6:R275-R283.
39. Fazakerley J.K., Pathak S., Scallan M., Amor S., Dyson H. Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons. Virology 1993, 195:627-637.
40. Frolov I., Agapov E., Hoffman T.A., Pragai B.M., Lippa M., Schlesinger S., Rice C.M. Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. J. Virol. 1999, 73:3854-3865.
41. Frolov I., Frolova E., Schlesinger S. Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA. J. Virol. 1997, 71:2819-2829.
42. Frolov I., Schlesinger S. Comparison of the effects of Sindbis virus and Sindbis virus replicons on host cell protein synthesis and cytopathogenicity in BHK cells. J. Virol. 1994, 68:1721-1727.
43. Frolov I., Schlesinger S. Translation of Sindbis virus mRNA: effects of sequences downstream of the initiating codon. J. Virol. 1994, 68:8111-8117.
44. Galanis E., Bateman A., Johnson K., Diaz R.M., James C.D., Vile R., Russell S.J. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther. 2001, 12:811-821.
45. Garcia-Hernandez M.L., Gray A., Hubby B., Kast W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007, 67:1344-1351.
46. Garcia-Hernandez M.L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68:861-869.
47. Gardner J.P., Frolov I., Perri S., Ji Y., MacKichan M.L., zur Megede J., Chen M., Belli B.A., Driver D.A., Sherrill S., Greer C.E., Otten G.R., Barnett S.W., Liu M.A., Dubensky T.W., Polo J.M. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 2000, 74:11849-11857.
48. Glasgow G.M., McGee M.M., Tarbatt C.J., Mooney D.A., Sheahan B.J., Atkins G.J. The Semliki Forest virus vector induces p53-independent apoptosis. J. Gen. Virol. 1998, 79(Pt 10):2405-2410.
49. Goldberg S.M., Bartido S.M., Gardner J.P., Guevara-Patino J.A., Montgomery S.C., Perales M.A., Maughan M.F., Dempsey J., Donovan G.P., Olson W.C., Houghton A.N., Wolchok J.D. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin. Cancer Res. 2005, 11:8114-8121.
50. Grabstein K.H., Urdal D.L., Tushinski R.J., Mochizuki D.Y., Price V.L., Cantrell M.A., Gillis S., Conlon P.J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986, 232:506-508.
51. Griffith I.P., Crook N.E., White D.O. Protection of mice against cancer by immunization with membranes but not purified virions from virus infected cancer cells. Br. J. Cancer 1975, 31:603-613.
52. Guan M., Rodriguez-Madoz J.R., Alzuguren P., Gomar C., Kramer M.G., Kochanek S., Prieto J., Smerdou C., Qian C. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Cancer Res. 2006, 66:1620-1629.
53. Hahn C.S., Hahn Y.S., Braciale T.J., Rice C.M. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2679-2683.
54. Hanke T., Barnfield C., Wee E.G., Agren L., Samuel R.V., Larke N., Liljeström P. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 2003, 84:361-368.
55. Heikkila J.E., Vaha-Koskela M.J., Ruotsalainen J.J., Martikainen M.W., Stanford M.M., McCart J.A., Bell J.C., Hinkkanen A.E. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010, 5:e8603.
56. Her Z., Kam Y.W., Lin R.T., Ng L.F. Chikungunya: a bending reality. Microbes Infect. 2009, 11:1165-1176.
57. Herweijer H., Latendresse J.S., Williams P., Zhang G., Danko I., Schlesinger S., Wolff J.A. A plasmid-based self-amplifying Sindbis virus vector. Hum. Gene Ther. 1995, 6:1161-1167.
58. Hidmark A.S., Nordstrom E.K., Dosenovic P., Forsell M.N., Liljeström P., Karlsson Hedestam G.B. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J. Virol. 2006, 80:7100-7110.
59. Hsu K.F., Hung C.F., Cheng W.F., He L., Slater L.A., Ling M., Wu T.C. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001, 8:376-383.
60. Huckriede A., Bungener L., Holtrop M., de Vries J., Waarts B.L., Daemen T., Wilschut J. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 2004, 22:1104-1113.
61. Hurtado A., Tseng J.C., Boivin C., Levin B., Yee H., Pampeno C., Meruelo D. Identification of amino acids of Sindbis virus E2 protein involved in targeting tumor metastases in vivo. Mol. Ther. 2005, 12:813-823.
62. Iijima Y., Ohno K., Ikeda H., Sawai K., Levin B., Meruelo D. Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Int. J. Cancer 1999, 80:110-118.
63. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 2001, 75:1205-1210.
64. Kamrud K.I., Coffield V.M., Owens G., Goodman C., Alterson K., Custer M., Murphy M.A., Lewis W., Timberlake S., Wansley E.K., Berglund P., Smith J. In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J. Virol. 2010, 84:7713-7725.
65. Ketola A., Hinkkanen A., Yongabi F., Furu P., Maatta A.M., Liimatainen T., Pirinen R., Bjorn M., Hakkarainen T., Makinen K., Wahlfors J., Pellinen R. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 2008, 68:8342-8350.
66. Kim T.W., Hung C.F., Juang J., He L., Hardwick J.M., Wu T.C. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther. 2004, 11:336-342.
67. + T cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1969-1974.
68. Klimp A.H., van der Vaart E., Lansink P.O., Withoff S., de Vries E.G., Scherphof G.L., Wilschut J., Daemen T. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther. 2001, 8:300-307.
69. Kohno A., Emi N., Kasai M., Tanimoto M., Saito H. Semliki Forest virus-based DNA expression vector: transient protein production followed by cell death. Gene Ther. 1998, 5:415-418.
70. Kuhn R.J., Niesters H.G., Hong Z., Strauss J.H. Infectious RNA transcripts from Ross River virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus. Virology 1991, 182:430-441.
71. Lachman L.B., Rao X.M., Kremer R.H., Ozpolat B., Kiriakova G., Price J.E. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther. 2001, 8:259-268.
72. Laust A.K., Sur B.W., Wang K., Hubby B., Smith J.F., Nelson E.L. VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model. Breast Cancer Res. Treat. 2007, 106:371-382.
73. Lee J.S., Lee J.H., Poo H., Kim M.S., Lee S.H., Sung M.H., Kim C.J. Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells. Int. J. Oncol. 2006, 28:649-654.
74. Leitner W.W., Bergmann-Leitner E.S., Hwang L.N., Restifo N.P. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006, 24:5110-5118.
75. Leitner W.W., Hwang L.N., Bergmann-Leitner E.S., Finkelstein S.E., Frank S., Restifo N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004, 22:1537-1544.
76. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., Dubensky T.W., Ying H., Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9:33-39.
77. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000, 60:51-55.
78. Leslie M.C., Zhao Y.J., Lachman L.B., Hwu P., Wu G.J., Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007, 14:316-323.
79. Liljeström P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N.Y.) 1991, 9:1356-1361.
80. Liljeström P., Lusa S., Huylebroeck D., Garoff H. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release. J. Virol. 1991, 65:4107-4113.
81. Lin C.T., Chang T.C., Shaw S.W., Cheng P.J., Huang C.T., Chao A., Soong Y.K., Lai C.H. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. Vaccine 2006, 24:6199-6207.
82. Lin C.T., Hung C.F., Juang J., He L., Lin K.Y., Kim T.W., Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol. Ther. 2003, 8:559-566.
83. Lopez S., Yao J.S., Kuhn R.J., Strauss E.G., Strauss J.H. Nucleocapsid-glycoprotein interactions required for assembly of alphaviruses. J. Virol. 1994, 68:1316-1323.
84. Luers A.J., Adams S.D., Smalley J.V., Campanella J.J. A phylogenomic study of the genus alphavirus employing whole genome comparison. Comp. Funct. Genomics 2005, 6:217-227.
85. Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines 2003, 2:447-459.
86. Lundstrom K. Semliki Forest virus vectors for large-scale production of recombinant proteins. Methods Mol. Med. 2003, 76:525-543.
87. Lundstrom K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim. Biophys. Acta 2003, 1610:90-96.
88. Lundstrom K., Abenavoli A., Malgaroli A., Ehrengruber M.U. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol. Ther. 2003, 7:202-209.
89. Lundstrom K., Rotmann D., Hermann D., Schneider E.M., Ehrengruber M.U. Novel mutant Semliki Forest virus vectors: gene expression and localization studies in neuronal cells. Histochem. Cell Biol. 2001, 115:83-91.
90. Lyons J.A., Sheahan B.J., Galbraith S.E., Mehra R., Atkins G.J., Fleeton M.N. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 2007, 14:503-513.
91. Maatta A.M., Liimatainen T., Wahlfors T., Wirth T., Vaha-Koskela M., Jansson L., Valonen P., Hakkinen K., Rautsi O., Pellinen R., Makinen K., Hakumaki J., Hinkkanen A., Wahlfors J. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int. J. Cancer 2007, 121:863-870.
92. Maatta A.M., Makinen K., Ketola A., Liimatainen T., Yongabi F.N., Vaha-Koskela M., Pirinen R., Rautsi O., Pellinen R., Hinkkanen A., Wahlfors J. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int. J. Cancer 2008, 123:1704-1711.
93. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 2000, 74:914-922.
94. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995, 1:1297-1302.
95. McLaughlin-Drubin M.E., Munger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009, 143:195-208.
96. Mokhtarian F., Zhang Z., Shi Y., Gonzales E., Sobel R.A. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J. Neuroimmunol. 1999, 95:43-54.
97. Moran T.P., Burgents J.E., Long B., Ferrer I., Jaffee E.M., Tisch R.M., Johnston R.E., Serody J.S. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007, 25:6604-6612.
98. Moran T.P., Collier M., McKinnon K.P., Davis N.L., Johnston R.E., Serody J.S. A novel viral system for generating antigen-specific T cells. J. Immunol. 2005, 175:3431-3438.
99. Murphy A.M., Morris-Downes M.M., Sheahan B.J., Atkins G.J. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther. 2000, 7:1477-1482.
100. Murphy A.M., Sheahan B.J., Atkins G.J. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector. Int. J. Cancer 2001, 94:572-578.
101. Naslund T.I., Uyttenhove C., Nordstrom E.K., Colau D., Warnier G., Jondal M., Van den Eynde B.J., Liljeström P. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 2007, 178:6761-6769.
102. Nelson E.L., Prieto D., Alexander T.G., Pushko P., Lofts L.A., Rayner J.O., Kamrud K.I., Fralish B., Smith J.F. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res. Treat. 2003, 82:169-183.
103. Ni B., Gao W., Zhu B., Lin Z., Jia Z., Zhou W., Zhao J., Wang L., Wu Y. Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model. Cancer Immunol. Immunother. 2005, 54:489-498.
104. Ni B., Lin Z., Zhou L., Wang L., Jia Z., Zhou W., Diciommo D.P., Zhao J., Bremner R., Wu Y. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene. Cancer Detect. Prev. 2004, 28:418-425.
105. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
106. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
107. Ohno K., Sawai K., Iijima Y., Levin B., Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat. Biotechnol. 1997, 15:763-767.
108. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88-91.
109. Olson K.E., Higgs S., Hahn C.S., Rice C.M., Carlson J.O., Beaty B.J. The expression of chloramphenicol acetyltransferase in Aedes albopictus (C6/36) cells and Aedes triseriatus mosquitoes using a double subgenomic recombinant Sindbis virus. Insect Biochem. Mol. Biol. 1994, 24:39-48.
110. Osterroth F., Garbe A., Fisch P., Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000, 95:1342-1349.
111. Perri S., Driver D.A., Gardner J.P., Sherrill S., Belli B.A., Dubensky T.W., Polo J.M. Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells. J. Virol. 2000, 74:9802-9807.
112. Petrakova O., Volkova E., Gorchakov R., Paessler S., Kinney R.M., Frolov I. Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in Mammalian cells. J. Virol. 2005, 79:7597-7608.
113. Pierro D.J., Myles K.M., Foy B.D., Beaty B.J., Olson K.E. Development of an orally infectious Sindbis virus transducing system that efficiently disseminates and expresses green fluorescent protein in Aedes aegypti. Insect Mol. Biol. 2003, 12:107-116.
114. Polo J.M., Belli B.A., Driver D.A., Frolov I., Sherrill S., Hariharan M.J., Townsend K., Perri S., Mento S.J., Jolly D.J., Chang S.M., Schlesinger S., Dubensky T.W. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4598-4603.
115. Pugachev K.V., Mason P.W., Shope R.E., Frey T.K. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 1995, 212:587-594.
116. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239:389-401.
117. Raju R., Huang H.V. Analysis of Sindbis virus promoter recognition in vivo, using novel vectors with two subgenomic mRNA promoters. J. Virol. 1991, 65:2501-2510.
118. Rausalu K., Iofik A., Ulper L., Karo-Astover L., Lulla V., Merits A. Properties and use of novel replication-competent vectors based on Semliki Forest virus. Virol. J. 2009, 6:33.
119. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002, 12:279-296.
120. Ren H., Boulikas T., Lundstrom K., Soling A., Warnke P.C., Rainov N.G. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J. Neurooncol. 2003, 64:147-154.
121. Rice C.M., Levis R., Strauss J.H., Huang H.V. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. J. Virol. 1987, 61:3809-3819.
122. Riezebos-Brilman A., Regts J., Chen M., Wilschut J., Daemen T. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine 2009, 27:701-707.
123. Riezebos-Brilman A., Walczak M., Regts J., Rots M.G., Kamps G., Dontje B., Haisma H.Y., Wilschut J., Daemen T. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007, 14:1695-1704.
124. Rodriguez-Madoz J.R., Liu K.H., Quetglas J.I., Ruiz-Guillen M., Otano I., Crettaz J., Butler S.D., Bellezza C.A., Dykes N.L., Tennant B.C., Prieto J., Gonzalez-Aseguinolaza G., Smerdou C., Menne S. Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J. Virol. 2009, 83:12266-12278.
125. Rodriguez-Madoz J.R., Prieto J., Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 2005, 12:153-163.
126. Rodriguez-Madoz J.R., Prieto J., Smerdou C. Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. Mol. Ther. 2007, 15:2164-2171.
127. Ryan M.D., Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994, 13:928-933.
128. Saito K., Uzawa K., Kasamatsu A., Shinozuka K., Sakuma K., Yamatoji M., Shiiba M., Shino Y., Shirasawa H., Tanzawa H. Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells. Br. J. Cancer 2009, 101:684-690.
129. Sawai K., Meruelo D. Cell-specific transfection of choriocarcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem. Biophys. Res. Commun. 1998, 248:315-323.
130. Schirmacher V., Forg P., Dalemans W., Chlichlia K., Zeng Y., Fournier P., von Hoegen P. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther. 2000, 7:1137-1147.
131. Shirako Y., Yamaguchi Y. Genome structure of Sagiyama virus and its relatedness to other alphaviruses. J. Gen. Virol. 2000, 81:1353-1360.
132. Simpson D.A., Davis N.L., Lin S.C., Russell D., Johnston R.E. Complete nucleotide sequence and full-length cDNA clone of S.A.AR86 a South African alphavirus related to Sindbis. Virology 1996, 222:464-469.
133. Sjöberg E.M., Suomalainen M., Garoff H. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology (N.Y.) 1994, 12:1127-1131.
134. Skoging U., Vihinen M., Nilsson L., Liljeström P. Aromatic interactions define the binding of the alphavirus spike to its nucleocapsid. Structure 1996, 4:519-529.
135. Smerdou C., Liljeström P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 1999, 73:1092-1098.
136. Smyth J.W., Fleeton M.N., Sheahan B.J., Atkins G.J. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther. 2005, 12:147-159.
137. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 1994, 58:491-562.
138. Suomalainen M., Liljeström P., Garoff H. Spike protein-nucleocapsid interactions drive the budding of alphaviruses. J. Virol. 1992, 66:4737-4747.
139. Tamm K., Merits A., Sarand I. Mutations in the nuclear localization signal of nsP2 influencing RNA synthesis, protein expression and cytotoxicity of Semliki Forest virus. J. Gen. Virol. 2008, 89:676-686.
140. Tan L., Xu B., Liu R., Liu H., Tan H., Huang W. Gene therapy for acute myeloid leukemia using sindbis vectors expressing a fusogenic membrane glycoprotein. Cancer Biol. Ther. 2010, 9:350-357.
141. Tennant B.C., Toshkov I.A., Peek S.F., Jacob J.R., Menne S., Hornbuckle W.E., Schinazi R.D., Korba B.E., Cote P.J., Gerin J.L. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004, 127:S283-S293.
142. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:4008-4027.
143. Tseng J.C., Daniels G., Meruelo D. Controlled propagation of replication-competent Sindbis viral vector using suicide gene strategy. Gene Ther. 2009, 16:291-296.
144. Tseng J.C., Granot T., Digiacomo V., Levin B., Meruelo D. Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 2010, 17:244-255.
145. Tseng J.C., Hurtado A., Yee H., Levin B., Boivin C., Benet M., Blank S.V., Pellicer A., Meruelo D. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res. 2004, 64:6684-6692.
146. Tseng J.C., Levin B., Hirano T., Yee H., Pampeno C., Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J. Natl. Cancer Inst. 2002, 94:1790-1802.
147. Tseng J.C., Levin B., Hurtado A., Yee H., Perez de Castro I., Jimenez M., Shamamian P., Jin R., Novick R.P., Pellicer A., Meruelo D. Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotechnol. 2004, 22:70-77.
148. Tseng J.C., Zanzonico P.B., Levin B., Finn R., Larson S.M., Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J. Nucl. Med. 2006, 47:1136-1143.
149. Tseng J.C., Zheng Y., Yee H., Levy D.E., Meruelo D. Restricted tissue tropism and acquired resistance to Sindbis viral vector expression in the absence of innate and adaptive immunity. Gene Ther. 2007, 14:1166-1174.
150. Tsetsarkin K., Higgs S., McGee C.E., De Lamballerie X., Charrel R.N., Vanlandingham D.L. Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis. 2006, 6:325-337.
151. Unno Y., Shino Y., Kondo F., Igarashi N., Wang G., Shimura R., Yamaguchi T., Asano T., Saisho H., Sekiya S., Shirasawa H. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin. Cancer Res. 2005, 11:4553-4560.
152. Vaha-Koskela M.J., Kallio J.P., Jansson L.C., Heikkila J.E., Zakhartchenko V.A., Kallajoki M.A., Kahari V.M., Hinkkanen A.E. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 2006, 66:7185-7194.
153. Vaha-Koskela M.J., Tuittila M.T., Nygardas P.T., Nyman J.K., Ehrengruber M.U., Renggli M., Hinkkanen A.E. A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J. Neurovirol. 2003, 9:1-15.
154. Vanlandingham D.L., Tsetsarkin K., Hong C., Klingler K., McElroy K.L., Lehane M.J., Higgs S. Development and characterization of a double subgenomic chikungunya virus infectious clone to express heterologous genes in Aedes aegypti mosquitoes. Insect Biochem. Mol. Biol. 2005, 35:1162-1170.
155. Velders M.P., McElhiney S., Cassetti M.C., Eiben G.L., Higgins T., Kovacs G.R., Elmishad A.G., Kast W.M., Smith L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001, 61:7861-7867.
156. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 1995, 87:581-586.
157. Wang K.S., Kuhn R.J., Strauss E.G., Ou S., Strauss J.H. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J. Virol. 1992, 66:4992-5001.
158. Wang X., Wang J.P., Maughan M.F., Lachman L.B. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res. 2005, 7:R145-R155.
159. Wang X., Wang J.P., Rao X.M., Price J.E., Zhou H.S., Lachman L.B. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res. 2005, 7:R580-R588.
160. Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol. 2005, 79:6005-6022.
161. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., Huang H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989, 243:1188-1191.
162. Yamaguchi Y., Shirako Y. Engineering of a Sagiyama alphavirus RNA-based transient expression vector. Microbiol. Immunol. 2002, 46:119-129.
163. Yamanaka R., Tsuchiya N., Yajima N., Honma J., Hasegawa H., Tanaka R., Ramsey J., Blaese R.M., Xanthopoulos K.G. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J. Neurosurg. 2003, 99:746-753.
164. Yamanaka R., Xanthopoulos K.G. Development of improved Sindbis virus-based DNA expression vector. DNA Cell Biol. 2004, 23:75-80.
165. Yamanaka R., Xanthopoulos K.G. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol. 2005, 24:317-324.
166. Yamanaka R., Yajima N., Tsuchiya N., Honma J., Tanaka R., Ramsey J., Blaese M., Xanthopoulos K.G. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J. Neurosurg. 2002, 97:1184-1190.
167. Yamanaka R., Zullo S.A., Ramsey J., Onodera M., Tanaka R., Blaese M., Xanthopoulos K.G. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther. 2001, 8:796-802.
168. Yamanaka R., Zullo S.A., Ramsey J., Yajima N., Tsuchiya N., Tanaka R., Blaese M., Xanthopoulos K.G. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 2002, 97:611-618.
169. Yamanaka R., Zullo S.A., Tanaka R., Blaese M., Xanthopoulos K.G. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J. Neurosurg. 2001, 94:474-481.
170. Yamanaka R., Zullo S.A., Tanaka R., Ramsey J., Blaese M., Xanthopoulos K.G. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg. Focus 2000, 9:e7.
171. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., Leitner W.W., Restifo N.P. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 1999, 5:823-827.
172. Zeng J., Fournier P., Schirrmacher V. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int. J. Oncol. 2004, 25:293-302.
173. Zhang J., Asselin-Paturel C., Bex F., Bernard J., Chehimi J., Willems F., Caignard A., Berglund P., Liljeström P., Burny A., Chouaib S. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Ther. 1997, 4:367-374.
174. Zhang J., Frolov I., Russell S.J. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J. Gene Med. 2004, 6:1082-1091.
175. Zhang Y.Q., Tsai Y.C., Monie A., Wu T.C., Hung C.F. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol. Ther. 2010, 18:692-699.
176. Zhao H., Garoff H. Role of cell surface spikes in alphavirus budding. J. Virol. 1992, 66:7089-7095.